Scarica l'app Stockscreener
31.31
0.14%
0.0568
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CPRX Giù?
Forum
Previsione
Precedente Chiudi:
$31.25
Aprire:
$31.22
Volume 24 ore:
1.27M
Relative Volume:
0.65
Capitalizzazione di mercato:
$3.83B
Reddito:
$588.99M
Utile/perdita netta:
$214.33M
Rapporto P/E:
18.59
EPS:
1.6844
Flusso di cassa netto:
$208.61M
1 W Prestazione:
+0.43%
1M Prestazione:
+22.06%
6M Prestazione:
+34.43%
1 anno Prestazione:
+28.68%
Intervallo 1D:
$31.22
$31.33
Intervallo di 1 settimana:
$31.00
$31.30
Portata 52W:
$19.05
$32.56
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Nome
Catalyst Pharmaceuticals Inc
Settore
Industria
Telefono
(305) 529-2522
Indirizzo
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
31.33 | 3.82B | 588.99M | 214.33M | 208.61M | 1.6844 |
VRTX
Vertex Pharmaceuticals Inc
|
432.28 | 109.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
646.33 | 68.12B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
823.15 | 50.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.93 | 39.85B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.86 | 31.96B | 742.00K | -1.37B | -1.07B | -7.0731 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-03-14 | Iniziato | Citigroup | Buy |
| 2024-03-07 | Iniziato | BofA Securities | Buy |
| 2023-12-21 | Iniziato | Oppenheimer | Outperform |
| 2022-08-24 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Ripresa | Piper Jaffray | Overweight |
| 2016-10-05 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Reiterato | ROTH Capital | Buy |
| 2014-09-16 | Reiterato | ROTH Capital | Buy |
| 2014-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2013-10-21 | Reiterato | Aegis Capital | Buy |
| 2013-09-24 | Iniziato | Maxim Group | Buy |
| 2013-09-06 | Reiterato | Aegis Capital | Buy |
| 2013-04-18 | Iniziato | Aegis Capital | Buy |
| 2012-08-27 | Aggiornamento | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Aggiornamento | Merriman | Sell → Neutral |
| 2009-05-29 | Downgrade | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Iniziato | Merriman Curhan Ford | Buy |
| 2007-11-28 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Iniziato | Stifel Nicolaus | Buy |
| 2007-01-05 | Iniziato | First Albany | Buy |
Mostra tutto
Catalyst Pharmaceuticals Inc Borsa (CPRX) Ultime notizie
Angelini Buyout And FIRDAPSE Settlement Reframe Catalyst Pharmaceuticals Story - Yahoo Finance
Angelini Pharma to buy Catalyst in deal worth $4.1 billion - MSN
Catalyst Pharmaceuticals Q1 earnings beat, Firdapse revenues rise Y/Y - MSN
Angelini Buyout And Firdapse Settlement Reframe Catalyst Pharmaceuticals Story - Sahm
CPRX Technical Analysis | Trend, Signals & Chart Patterns | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
Catalyst Pharmaceuticals, Inc.Common Stock (NQ: CPRX - FinancialContent
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
Angelini Interest Puts Catalyst Pharmaceuticals Rare Disease Value In Focus - Sahm
Catalyst Pharmaceuticals: Angelini Deal Caps A Potentially Better Story (NASDAQ:CPRX) - Seeking Alpha
CPRX SWOT Analysis: Strong Financials Amidst Market Challenges R - GuruFocus
Catalyst Pharmaceuticals (CPRX) Q1 EPS Beat Reinforces High Margin Bull Narratives - Sahm
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y - Yahoo Finance
Trading the Move, Not the Narrative: (CPRX) Edition - Stock Traders Daily
Catalyst Pharmaceuticals earnings beat by $0.06, revenue topped estimates - Investing.com Canada
Catalyst Pharmaceuticals (CPRX) Announces Suspension of Guidance Updates - GuruFocus
Catalyst Pharmaceuticals, Inc. Q1 2026 earnings preview - MSN
CPRX Reports Impressive Q1 Revenue Growth - GuruFocus
Catalyst Pharma Reports Higher Revenue, Suspends Earnings Guidance - TipRanks
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Catalyst Pharmaceuticals 1Q EPS 50c >CPRX - Moomoo
Profit rises at Catalyst Pharmaceuticals (NASDAQ: CPRX) on Q1 2026 results - Stock Titan
Catalyst Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise - marketscreener.com
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results - The Manila Times
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Reports Q1 Revenue $149.4M, vs. FactSet Est of $149.5M - marketscreener.com
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.79 per Share, vs. FactSet Est of $0.65 - marketscreener.com
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.79 per Share, Vs. FactSet Est of $0.65 - Moomoo
BRIEF-Catalyst Pharmaceuticals Q1 Revenue USD 149.4 Million Vs. IBES Estimate USD 148.2 Million - TradingView
Catalyst Pharma (NASDAQ: CPRX) posts Q1 profit ahead of Angelini deal - Stock Titan
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Scores 7/10 Fundamental Rating in Affordable Growth Screen - ChartMill
Angelini Pharma agrees $4.1bn Catalyst Pharmaceuticals acquisition - Yahoo Finance
Catalyst Pharmaceuticals (CPRX) Set to Report Q1 Earnings with P - GuruFocus
Catalyst FIRDAPSE Deal Extends Exclusivity To 2035 And Shapes Angelini Bid - Sahm
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc.CPRX - The AI Journal
Vanguard Group Inc. Lowers Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Buyout And FIRDAPSE Patents Reframe Investor Outlook - Yahoo Finance
Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1B - MSN
Family-run Angelini Pharma buys Catalyst Pharmaceuticals for over 4 billion - MSN
FinancialContentCatalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc.CPRX - FinancialContent
Catalyst Pharmaceuticals Cut to Neutral From Buy by Citigroup - Moomoo
MSN Money - MSN
Citigroup downgrades Catalyst Pharmaceuticals (CPRX) - MSN
Catalyst Pharmaceuticals (NASDAQ:CPRX) Lowered to "Hold" Rating by Robert W. Baird - MarketBeat
CPRX Downgraded by Citigroup -- Price Target Lowered to $31.50 - GuruFocus
Citi Downgrades Catalyst Pharmaceuticals(CPRX.US) to Hold Rating, Cuts Target Price to $31.5 - Moomoo
European company to acquire Miami pharma business for $4.1 billion - The Business Journals
Oppenheimer Downgrades Catalyst Pharmaceuticals to Market Perform From Outperform - Moomoo
Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1 billion - Yahoo Finance
Catalyst Pharmaceuticals stock (US14888U1016): Angelini Pharma to buy CPRX for $4.1 billion in cash - AD HOC NEWS
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease - Mynewsdesk
Catalyst Pharmaceuticals Inc Azioni (CPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Catalyst Pharmaceuticals Inc Azioni (CPRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Harper Molly | Director |
Dec 12 '25 |
Sale |
23.25 |
26,746 |
621,920 |
2,360 |
0.06%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):